Literature DB >> 21875933

Proteolytic activation of pro-macrophage-stimulating protein by hepsin.

Rajkumar Ganesan1, Ganesh A Kolumam, S Jack Lin, Ming-Hong Xie, Lydia Santell, Thomas D Wu, Robert A Lazarus, Amitabha Chaudhuri, Daniel Kirchhofer.   

Abstract

Macrophage-stimulating protein (MSP) is a plasminogen-related growth factor and ligand for the receptor tyrosine kinase RON. The MSP/RON system promotes wound healing and invasive tumor growth and suppresses proinflammatory immune response. MSP binding to RON requires proteolytic conversion of the inactive single-chain form (pro-MSP) into the disulfide-linked α/β heterodimer. The pro-MSP cleavage sequence (Ser-Lys-Leu-Arg(483)↓Val(484)) closely matches the substrate recognition sequences of hepsin, a type II transmembrane serine protease, that is overexpressed in several cancers. Here, we show that recombinant hepsin cleaves pro-MSP at the consensus site Arg(483)-Val(484) with superior efficiency compared with the known activators MT-SP1 and hepatocyte growth factor activator (HGFA). At least 50% of pro-MSP was processed within 1 hour at a hepsin concentration of 2.4 nmol/L and at a molar enzyme to substrate ratio of 1:500. An uncleavable single-chain variant of MSP weakly bound to a RON-Fc fusion protein, whereas hepsin-cleaved MSP bound with a K(D) of 10.3 nmol/L, suggesting that the high-affinity binding site in MSP β-chain was properly formed. LNCaP prostate cancer cells overexpressing hepsin on the cell surface efficiently activated pro-MSP, which was blocked by a specific anti-hepsin antibody. Incubation of pro-MSP with hepsin led to robust RON-mediated phosphorylation of mitogen-activated protein kinase, ribosomal S6 protein, and Akt in human A2780 ovarian carcinoma cells stably expressing RON protein. In macrophages, pro-MSP with hepsin induced chemotaxis and attenuated lipopolysaccharide-dependent production of nitric oxide. These findings suggest that the MSP/RON signaling pathway may be regulated by hepsin in tissue homeostasis and in disease pathologies, such as in cancer and immune disorders. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875933     DOI: 10.1158/1541-7786.MCR-11-0004

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  25 in total

1.  Inhibiting alternative pathway complement activation by targeting the factor D exosite.

Authors:  Kenneth J Katschke; Ping Wu; Rajkumar Ganesan; Robert F Kelley; Mary A Mathieu; Philip E Hass; Jeremy Murray; Daniel Kirchhofer; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 2.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 3.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

4.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

5.  Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Mol Model       Date:  2017-08-19       Impact factor: 1.810

Review 6.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

7.  Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.

Authors:  Vishnu C Damalanka; Scott A Wildman; James W Janetka
Journal:  Medchemcomm       Date:  2019-07-18       Impact factor: 3.597

Review 8.  Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

Authors:  Srinivas Nandana; Leland Wk Chung
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

Review 9.  Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4.

Authors:  Johanna I Partanen; Topi A Tervonen; Juha Klefström
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-09-23       Impact factor: 6.237

10.  Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.

Authors:  Aaron C Mitchell; Deepti Kannan; Sean A Hunter; R Andres Parra Sperberg; Cheryl H Chang; Jennifer R Cochran
Journal:  J Biol Chem       Date:  2018-01-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.